-
Mashup Score: 7Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich - 13 hour(s) ago
John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company’s “radioligand first, isotope second” approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 16Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li - 15 hour(s) ago
Roger Li discusses findings from a patient panel at the BCAN Think Tank, focusing on decision-making in BCG-unresponsive and muscle-invasive bladder cancer treatment. He emphasizes the emotional journey patients undergo and the importance of empowering them with information. Dr. Li highlights several patient stories, demonstrating diverse treatment choices ranging from bladder-sparing approaches…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Patient perspectives on #BladderCancer: Balancing treatment options and shared decision-making. @UrogerliMD @MoffittNews joins @UroDocAsh @MDAndersonNews discussing findings from a patient panel at #BCANTT24 on BCG-unresponsive and #MIBC > https://t.co/32l0Ru0lek @BladderCancerUS https://t.co/EKYoJVG2f7
-
-
Mashup Score: 8SLICE: Revolutionizing Surgical Training with Ultra-Realistic Simulation - Ahmed Ghazi - 16 hour(s) ago
Zach Klaassen interviews Ahmed Ghazi about his work in robotic simulation. Dr. Ghazi shares his journey from laparoscopic surgery in Europe to robotic surgery in the US, emphasizing the need for realistic surgical training tools. He developed 3D-printed, hydrogel organs that simulate bleeding, enhancing training realism. At Hopkins, Dr. Ghazi established SLICE (Surgical Learning and Innovation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
SLICE: Revolutionizing surgical training with ultra-realistic simulation. @aghazimd joins @zklaassen_md to discuss his work in the field of his work in robotic simulation and his journey from laparoscopic surgery in Europe to robotic in the US https://t.co/w421ofE32C https://t.co/A9lmfAeA5L
-
-
Mashup Score: 5Predicting Response to Bipolar Androgen Therapy: A Blood-Based Biomarker Approach - Samuel Denmeade - 17 hour(s) ago
Alicia Morgans interviews Samuel Denmeade about the TRANSFORMER trial and Bipolar Androgen Therapy (BAT) for prostate cancer. Dr. Denmeade explains that the trial, involving 200 patients, compared high-dose testosterone therapy to enzalutamide in treating hormone-resistant prostate cancer. Surprisingly, both treatments showed similar efficacy, with each offering about a six-month response…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Predicting response to bipolar androgen therapy: a blood-based biomarker approach. Samuel Denmeade, MD @hopkinskimmel joins @CaPsurvivorship @DanaFarber to discuss the #TRANSFORMER trial and Bipolar Androgen Therapy for prostate cancer. #WatchNow > https://t.co/LB0UetgCqA https://t.co/Yutgt42C9T
-
-
Mashup Score: 4Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis - 18 hour(s) ago
Maria De Santis discusses managing frail patients with metastatic hormone-sensitive prostate cancer. Dr. De Santis explains the importance of defining frailty, which involves five key factors: unintended weight loss, weakness, low physical activity, difficulty lifting objects, and mobility issues. She highlights the necessity of evaluating frailty using tools like the G8 screening and emphasizes…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Managing frail patients with metastatic hormone-sensitive #ProstateCancer. @mdesantis234 joins @CaPsurvivorship @DanaFarber to explain the importance of defining frailty, which involves five key factors. #WatchNow on UroToday > https://t.co/YiMNSCNbSW https://t.co/Aez2DTyDyJ
-
-
Mashup Score: 10BRCA2 and Beyond: Unraveling Genetic Drivers of Prostate Cancer Aggressiveness - Hiba Khan - 19 hour(s) ago
Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan’s study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
BRCA2 and Beyond: Unraveling genetic drivers of #ProstateCancer aggressiveness. @HibaMKhanMD @fredhutch joins @AndreaMiyahira @PCFnews to discuss germline genetic associations and gene-specific associations and potential disparities in testing > https://t.co/NOoVEq03Fe https://t.co/7kzkRJ8aoM
-
-
Mashup Score: 11The Future State of Race & Ethnicity in Urology: Urology Workforce Projection from 2021-2061 - Efe Chantal Ghanney Simons & Ashley Appleton - 20 hour(s) ago
Ruchika Talwar is joined by Ashley Appleton and Efe Chantal Ghanney-Simons, discussed the future racial and ethnic composition of the urology workforce. The discussion, based on their study “The Future State of Race Ethnicity in Urology: A Workforce Projection From 2021-2061,” highlighted the slow growth of underrepresented minorities in urology compared to their increasing proportion in the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The future state of race & ethnicity in #Urology: Urology workforce projection from 2021-2061. @EfeCGhanney and @AAppletonMD2Be join @RuchikaTalwarMD to discuss this important issue and the slow growth of underrepresented minorities in urology > https://t.co/ZB8gneccxP https://t.co/zmD8xAEBHI
-
-
Mashup Score: 10AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser - 21 hour(s) ago
Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
AUA 2024 #UrothelialCarcinoma highlights. @WSmelser @WashU_Uro joins @UroCancerMD @VUMCurology to discuss key takeaways, rapid advancements and significant improvements > https://t.co/dLGvcdWzeb #NMIBC https://t.co/JHV63bqGpP
-
-
Mashup Score: 11Introducing the Kidney Stone Collaborative: A New Nonprofit for Kidney Stone Patients - Justin Ziemba - 22 hour(s) ago
Ruchika Talwar interviews Justin Ziemba about a significant development in kidney stone disease advocacy and research. Dr. Ziemba announces the creation of the Kidney Stone Collaborative (KSC), a new nonprofit organization dedicated to improving research and advocacy for kidney stone patients. He explains that this initiative has been months in the making, involving scientific experts, patient…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Introducing the #KidneyStone collaborative: A new nonprofit for kidney stone patients. @Justin_Ziemba @PennMedicine joins @RuchikaTalwarMD @VUMCurology to discuss significant developments in kidney stone disease advocacy and research > https://t.co/OiiNFtOCWP https://t.co/xVHyAV01tb
-
-
Mashup Score: 10RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca - 23 hour(s) ago
Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors. Dr. Conteduca discusses the trial design, which randomizes patients to receive either radium-223 followed by docetaxel or vice versa. The primary endpoint is…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#RAPSON trial explores radium223 and docetaxel sequencing in #mCRPC. Vincenza Conteduca joins @neerajaiims to discuss trial design, preliminary results, and the importance of focusing on quality of life in mCRPC treatment. #WatchNow > https://t.co/MY2IcKlQFh https://t.co/cWqsxiVBOs
-
Advancing #Radiopharmaceuticals: Targeting strategies and isotope selection in cancer therapy. John Babich, PhD @Ratio_Tx and Oliver Sartor, MD @MayoClinic emphasize the importance of targeting and retention in tumor tissues > https://t.co/9wfv2h5NCt https://t.co/WqTfXEhDla